CRIS Current Research Information System

ROSTI, GIANANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.577
EU - Europa 6.043
AS - Asia 5.922
AF - Africa 429
SA - Sud America 423
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 5
Totale 21.416
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.509
GB - Regno Unito 1.872
SG - Singapore 1.786
CN - Cina 1.721
VN - Vietnam 1.149
SE - Svezia 789
DE - Germania 753
IT - Italia 734
HK - Hong Kong 431
NL - Olanda 374
RU - Federazione Russa 349
IN - India 343
BR - Brasile 305
UA - Ucraina 251
FR - Francia 237
IE - Irlanda 214
ZA - Sudafrica 141
JP - Giappone 137
EE - Estonia 123
TG - Togo 109
KR - Corea 101
CI - Costa d'Avorio 80
JO - Giordania 70
BG - Bulgaria 64
CH - Svizzera 63
FI - Finlandia 59
AR - Argentina 48
CA - Canada 46
NG - Nigeria 42
ID - Indonesia 37
BE - Belgio 35
AT - Austria 28
EC - Ecuador 25
PL - Polonia 25
TR - Turchia 25
IR - Iran 23
SC - Seychelles 23
GR - Grecia 22
AU - Australia 15
CL - Cile 15
MX - Messico 15
BD - Bangladesh 13
ES - Italia 12
RO - Romania 12
MY - Malesia 10
PY - Paraguay 10
LB - Libano 9
MA - Marocco 9
AE - Emirati Arabi Uniti 7
CO - Colombia 7
IQ - Iraq 7
TW - Taiwan 7
IL - Israele 6
KE - Kenya 6
PK - Pakistan 6
SA - Arabia Saudita 6
TH - Thailandia 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
EG - Egitto 5
VE - Venezuela 5
NP - Nepal 4
TN - Tunisia 4
UG - Uganda 4
EU - Europa 3
HN - Honduras 3
NO - Norvegia 3
PE - Perù 3
PH - Filippine 3
PT - Portogallo 3
AL - Albania 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
LT - Lituania 2
MV - Maldive 2
NZ - Nuova Zelanda 2
OM - Oman 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GM - Gambi 1
HR - Croazia 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
MW - Malawi 1
RW - Ruanda 1
SI - Slovenia 1
SR - Suriname 1
SV - El Salvador 1
Totale 21.413
Salva come PNG Salva come JPEG
Città #
Southend 1.692
Singapore 1.157
Fairfield 1.032
Ashburn 868
Chandler 782
Woodbridge 543
Houston 501
Wilmington 489
Seattle 477
Hong Kong 424
Dong Ket 406
Cambridge 347
Princeton 327
Ann Arbor 317
Beijing 292
Hefei 224
Dublin 214
Boardman 209
Nanjing 167
Santa Clara 166
Ho Chi Minh City 159
Westminster 145
Hanoi 132
Padova 131
Jacksonville 130
Bologna 128
Tokyo 121
Dallas 109
Lomé 109
Los Angeles 93
Berlin 91
Seoul 90
New York 89
Abidjan 79
Saint Petersburg 73
Buffalo 72
Amman 70
Jinan 70
Shenyang 63
Sofia 63
Turin 62
Changsha 57
Bern 55
Milan 54
San Diego 54
Helsinki 53
Nanchang 53
Hebei 51
Falls Church 45
Munich 44
Redondo Beach 43
Jiaxing 42
Abeokuta 38
São Paulo 38
Guangzhou 35
Brussels 34
Tianjin 34
Bremen 32
Medford 32
Redmond 32
Frankfurt am Main 31
Zhengzhou 31
Falkenstein 28
Mülheim 27
Norwalk 26
Dearborn 25
Florence 25
Jakarta 25
Bengaluru 24
Shanghai 23
Warsaw 23
Des Moines 22
Phoenix 22
London 21
Nuremberg 21
Rome 21
Haikou 20
Da Nang 19
Hangzhou 18
Taizhou 18
Chengdu 17
Hải Dương 17
Haiphong 16
Washington 16
Chicago 15
Mahé 15
Redwood City 15
Toronto 15
Yubileyny 15
Brooklyn 14
Mountain View 14
Wuhan 14
Boston 13
Ningbo 13
Bühl 12
Taiyuan 12
Harbin 11
Olalla 11
Verona 11
Istanbul 10
Totale 14.285
Salva come PNG Salva come JPEG
Nome #
Consensus conference on the management of tumor lysis syndrome. 392
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 362
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 315
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 269
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 269
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 265
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 258
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 254
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 242
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 235
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 231
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 224
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 221
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 206
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 202
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 200
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 199
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 195
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 192
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 192
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 189
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 179
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 178
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 177
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 176
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 176
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 176
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 166
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 164
A review of the European LeukemiaNet recommendations for the management of CML 164
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 162
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 162
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 160
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 160
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 158
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 158
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 156
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. 156
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 155
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 155
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 154
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? 152
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 151
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 150
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 149
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 148
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 148
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 148
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 147
Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. 147
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 145
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 144
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 143
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 143
Leucemia mieloide cronica: terapia molecolare 142
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 141
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia 139
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 138
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 138
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 137
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 137
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 136
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 135
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia 134
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 133
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 133
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 132
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 132
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 132
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 132
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 131
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 129
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 128
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 128
Explaining the in vitro and in vivo differences in leukemia therapy. 127
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 127
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. 126
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 126
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 126
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 125
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 124
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 124
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 124
Diagnosis and classification of the risk 123
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 123
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 121
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 121
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 120
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 119
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 119
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 118
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. 116
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 115
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib 115
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 115
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 114
Imatinib mesylate in the treatment of hematologic malignancies. 114
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 113
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance 112
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type 112
Totale 16.125
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.502 0 0 0 0 0 83 48 141 240 95 177 718
2021/20222.827 342 88 200 257 269 171 53 177 110 193 463 504
2022/20233.104 378 494 174 378 221 224 124 170 505 64 247 125
2023/2024886 47 134 54 89 71 217 49 50 22 51 65 37
2024/20253.241 95 505 289 213 382 160 231 81 37 441 129 678
2025/20263.627 528 650 781 477 846 345 0 0 0 0 0 0
Totale 21.861